Navigation Links
New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease
Date:4/26/2012

LEOPATRA-PD), and PD with unsatisfactory control of early-morning motor symptoms (RECOVER™) was conducted*. Individual items assessing apathy, anhedonia, anxiety, anxiety/depression, depression and fatigue were identified from the scales used in these studies  - the Non-Motor Symptoms Scale (NMSS), the Beck Depression Inventory (BDI-II), the 39-item Parkinson's Disease Questionnaire (PDQ-39), the 8-item Parkinson's disease questionnaire (PDQ-8) and the 5-item EuroQol Group questionnaire (EQ-5D).

  • Depression: Compared with placebo, improvements were observed with rotigiotine transdermal system in all 3 items assessing feelings of depression (p<0.02)
  • Anxiety/depression: Compared with placebo, improvements were observed with rotigotine transdermal system in the 1 item assessing anxiety/depression in 2 of 3 studies (p<0.03)
  • Anxiety: Compared with placebo, an improvement was observed with rotigotine transdermal system in 1 of 3 items assessing anxiety (p=0.002)
  • Apathy: Compared with placebo, improvements were observed with rotigotine transdermal system in all 3 items assessing apathy (p<0.04)
  • Anhedonia: Compared with placebo, improvements were observed with rotigotine transdermal system in 1 of 2 items assessing anhedonia (p=0.026)
  • Fatigue: Compared with placebo, improvements were observed with rotigotine transdermal system in 2 of 3 items assessing fatigue (p less than 0.003)

ABSTRACT  TITLE: Rotigotine transdermal system improves pain in patients with Parkinson's disease: A post-hoc analysis of patients reporting pain in the RECOVER study

RECOVER™* (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine) was a double-blind, placebo-controlled  study (n=287) that demonstrated significant improvements in early-morn
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
4. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
5. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
10. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... Naperville, IL (PRWEB) July 30, 2014 ... requirements of business and technology startups is now ... leading full-service, marketing agency based in the Chicago ... categories as software and information technology (IT), services, ... more. , Marketing disciplines critical to startup ...
(Date:7/30/2014)... household income of its residents is the most important factor ... avoidable hospital visits conditions that could be better managed ... treated at an early stage, according to a report released ... , An analysis of hospital billing records and demographic ... Jersey found that as an area,s per capita income rises, ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 The ... during the five years to 2014. Following a multiyear ... to beneficial demographic trends, the expansion of private healthcare ... IBISWorld estimates that Hearing Aid Clinics industry ... to $2.7 billion during the five years to 2014. ...
(Date:7/30/2014)... San Francisco, California (PRWEB) July 30, 2014 ... to reach USD 5,440.5 million by 2020, growing at ... according to a new study by Grand View Research, ... increasing prevalence of deafness is expected to serve this ... increasing usage rates of 100% digital hearing aid technology ...
(Date:7/30/2014)... genetic mutation linked to obesity respond differently to pictures ... do not have the genetic mutation, according to a ... of Clinical Endocrinology & Metabolism ( JCEM ). ... typically results from a combination of eating too much, ... consumption of appetizing foods that are high in calories ...
Breaking Medicine News(10 mins):Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay News) ... of tens of thousands of Americans at risk for ... But these medical devices have gotten a bad ... or leads, that connect the ICD to the heart ...
... and Hong Kong have conducted a comprehensive study to ... female attractiveness. The study, published in the Journal ... young, tall and long armed women were considered the ... determining factor for evolutionary, social and economic success," said ...
... Mayo Clinic researchers and their international colleagues have discovered ... subset of women when taking aromatase inhibitors to treat ... painful that many women halt their lifesaving medication. The ... Journal of Clinical Oncology . "Many women stop ...
... Ellin Holohan HealthDay Reporter , MONDAY, Sept. 27 ... predict stroke patients, risk of dying in the hospital and ... new Canadian study. Hospitals also can use the ... study author Dr. Eric Smith, assistant professor of neurology at ...
... Therapeutics, Inc. is presenting new data in five posters ... with the company,s radioprotectant Ex-RAD at the 56th Annual ... in Maui, Hawaii. In vivo studies show that ... survival versus placebo-treated groups in mice exposed to lethal ...
... The International Robotic Urology Symposium+2011 will take place Jan. ... will view numerous 3D and 2D surgeries (each morning), ... throughout the United States and abroad. , Lectures and ... and pediatrics as well as alternatives therapies to treat ...
Cached Medicine News:Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 2Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 3Health News:Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies 2Health News:Mayo collaboration finds source of breast drug side effect 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 3Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: